MPO-ANCA positive glomerulonephritis during PD-1 inhibitor combined with anti-CTLA4 antibody in lung cancer

Letter Rheumatology

Immune checkpoint inhibitors as potential triggers for ANCA vasculitis

Faten Aqeel et al.

RMD OPEN (2022)

Article Pathology

ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab

Meral Uner et al.

Summary: Cancer immunotherapy with immune checkpoint inhibitors has been successful in various cancer types, but specific side effects, such as immune-related adverse events (irAEs) in the kidney, are rare. This case report describes a patient treated with pembrolizumab for squamous cell carcinoma who developed infectious enterocolitis and ANCA-related diffuse necrotizing crescentic glomerulonephritis, potentially linked to the treatment.

VIRCHOWS ARCHIV (2021)

添加到收藏夹

Review Urology & Nephrology

A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease

Abhijat Kitchlu et al.

Summary: This study summarized the association between immune checkpoint inhibitors and glomerular diseases, revealing various forms of diseases including pauci-immune glomerulonephritis, podocytopathies, and C3GN. Most patients experienced complete or partial recovery from acute kidney injury, but a portion of patients still required dialysis.

KIDNEY INTERNATIONAL REPORTS (2021)

添加到收藏夹

Article Urology & Nephrology

Efficacy of Plasmapheresis in Nivolumab-Associated ANCA Glomerulonephritis: A Case Report and Pathophysiology Discussion

Reda Laamech et al.

Summary: Immune checkpoint inhibitors (ICIs) have improved cancer treatments, but can lead to immune-related adverse events, including renal damage. This report describes a case of ANCA-positive vasculitis after nivolumab therapy, emphasizing the importance of recognizing and treating drug-induced renal injuries effectively.

CASE REPORTS IN NEPHROLOGY AND DIALYSIS (2021)

添加到收藏夹

Article Urology & Nephrology